Prostamax: A Khavinson Tetrapeptide Bioregulator Studied in Prostate Tissue Models

Research summary. Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro / KEDP) belonging to the Khavinson "peptide bioregulator" family. The published literature describes effects on heterochromatin condensation, lymphocyte function, and prostate-tissue inflammation endpoints in rodent models. As with the rest of the Khavinson tripeptide and tetrapeptide series, the proposed mechanism centres on direct chromatin interaction and gene-expression modulation rather than canonical receptor binding, and the literature is dominated by a single research programme.

Molecular profile

• Sequence: Lys-Glu-Asp-Pro (KEDP)
• Molecular formula: C₂₀H₃₃N₅O₉
• Molecular weight: ~487.5 g/mol
• PubChem CID: 9848296
• Synonyms: SCHEMBL6660498; KEDP tetrapeptide

Mechanism of action

Prostamax is described in the Khavinson framework as a tissue-targeted "bioregulator" whose activity is interpreted via direct chromatin engagement rather than cell-surface receptor binding:

• Heterochromatin decondensation. Reported across the Khavinson series; in the case of Prostamax, decondensation has been described in lymphocyte and prostate-tissue cell preparations from aged donors, interpreted as reactivation of age-silenced gene loci.
• Tissue-selective gene-expression modulation. Proposed activity profile centres on prostate epithelium and on immune cells, with reported effects on lymphocyte function.
• Anti-inflammatory effects in prostate tissue. Reported in chronic-inflammation rodent models of the prostate.

The central mechanistic claim — direct sequence-specific or sequence-preference DNA interaction by short Khavinson peptides — remains debated and is not firmly established outside the originating group.

Preclinical research highlights

Chronic prostatic inflammation models. Rodent research on chronic prostatitis-type models has reported reduced inflammatory infiltrate and improved histological endpoints in prostate tissue following Prostamax administration.

Lymphocyte function. Reported effects include modulation of lymphocyte proliferation and increased expression of certain immune-relevant gene loci in cell-culture work.

Heterochromatin decondensation. Decondensation of heterochromatin in lymphocytes from older animal donors has been reported as a characteristic effect, consistent with the broader Khavinson tetrapeptide pattern.

Anti-ageing endpoint research. Long-term rodent administration studies from the Khavinson group have reported improvements in standard biological-ageing endpoints, although study durations have generally been insufficient to evaluate cancer-prevention claims.

Limitations of the evidence base

The Prostamax literature shares the limitations characteristic of the Khavinson bioregulator family:

• The published evidence base is concentrated in a single research programme.
• Independent replication outside Russia is limited.
• The proposed direct-DNA-interaction mechanism is not firmly established by independent biochemical work.
• Long-term controlled efficacy studies sufficient to evaluate cancer-prevention claims have not been completed.

Researchers should treat the Prostamax literature as hypothesis-generating rather than confirmatory.

Current research status

Prostamax is an investigational research peptide. It is not approved by the FDA for any indication. It is not in late-stage clinical development in any major Western trial registry.

For research-supplier contexts, Prostamax is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

• Prostamax is a Khavinson-family tetrapeptide (Lys-Glu-Asp-Pro) studied for prostate-inflammation and lymphocyte-function endpoints in rodent models.
• The proposed mechanism centres on chromatin interaction and gene-expression modulation rather than receptor binding.
• Reported preclinical effects include reduced prostatic inflammation in rodent chronic-prostatitis models, lymphocyte-function modulation, and heterochromatin decondensation.
• The published literature is dominated by a single research programme; independent replication is limited.
• Prostamax is not an FDA-approved drug.

References

1. Khavinson VK, Solovyev AY, Tarnovskaya SI, Lin'kova NS. Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression. Bull Exp Biol Med. 2014;156(5):635–639.
2. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149.

---

This article is provided for educational and research purposes only. Prostamax is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.